HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only figure Alert me when this article is cited Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armendáriz-Borunda, J Articles by García, L Search for Related Content PubMed PubMed Citation Articles by Armendáriz-Borunda, J Articles by García, L

A pilot study in patients with established advanced liver fibrosis using pirfenidone

¹ Institute for Molecular Biology in Medicine and Gene Therapy, Guadalajara, Jalisco, México, and OPD Civil Hospital of Guadalajara, Guadalajara, Jalisco
² Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
³ Institute of Chronic Degenerative Diseases, Guadalajara, Jalisco, México
⁴ Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
⁵ Unit of Genomic Medicine, General Hospital of México, México
⁶ Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
⁷ OPD Civil Hospital of Guadalajara, Guadalajara, Jalisco, México
⁸ Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México

Correspondence to:
Correspondence to:
Dr J Armendáriz-Borunda
Institute for Molecular Biology in Medicine and Gene Therapy, Apdo Postal 2-123, Guadalajara, Jalisco, México 44281; armendbo@cucs.udg.mx

Keywords: liver fibrosis; pirfenidone

The first 150 words of the full text of this article appear below.

Cirrhosis represents the third cause of mortality among Mexican people of productive age.¹ Several drugs have been tested in the clinical scenario^2,3 although conclusive evidence concerning drug efficacy has proven elusive.

PFD is an orally bioavailable pyridone derivative (5-methyl-1-phenyl-2-(1H)-pyridone) that affects a variety of profibrogenic cytokines and its mechanism of action mostly resides in its anti-inflammatory and antifibrotic activity.^4–6 Here we present data obtained from a pilot clinical trial evaluating the safety and efficacy of PFD in 15 patients with established advanced liver disease caused by hepatitis C virus chronic infection. This is the first report showing improvements in liver histology (that is, necrosis, inflammation, steatosis, fibrosis, and cell regeneration) 12 months after PFD therapy. Colour Doppler ultrasound guided liver biopsies were obtained at baseline and after 12 months of PFD treatment and evaluated for stage of fibrosis and grade of activity according to the modified histological activity index (HAI) . . . [Full text of this article]

This article has been cited by other articles:

				M. E. Cho, D. C. Smith, M. H. Branton, S. R. Penzak, and J. B. Kopp Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 906 - 913. [Abstract] [Full Text] [PDF]

				F. S. Shihab Do We Have a Pill for Renal Fibrosis? Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 876 - 878. [Full Text] [PDF]